Correction

Premium

In the 4/5/2005 issue of Cell-Based Assay News, the article “Euroscreen Wins Addional Aequorin Screening Patent; Seeks to Expand Instrument Partners” contained factual errors. EuroScreen has approximately 50 employees in R&D, not 15 as stated in the article. In addition, EuroScreen uses the FMAT8100 high-throughput screening system, which is currently available from Applied Biosystems, and not the discontinued FMAT as stated.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.